Home Contact Site Map Search Submit Value through Innovation05 October 2014 News Corporate Profile Global Activities Corporate Responsibility Careers Research & Development Clinical Trials Medical Information Products Partnering Page content jump to main navigation jump to meta navigation Boehringer Ingelheim New resource for journalists Oncology Websites No flash player detected. For optimized usage of this website your browser should support shockwave flash. For downloading see Macromedia Flash Player Discover oncology website Life with Lung Cancer Giotrif® Plk inhibition Our Global Activities Our Countries A-Z Albania Argentina Armenia Austria Australia Azerbaijan Bahrain Belarus Belgium Bosnia and Herzegovina Brazil Bulgaria Canada Chile China Colombia Croatia Cyprus Czech Republic Denmark Ecuador Egypt Estonia Ethiopia Finland France Georgia Germany Germany Headquarters Greece Ghana Hong Kong Hungary India Indonesia Iraq Irland Israel Italy Japan Jordan Kazakhstan Kenya Kirghizia Kuweit Latvia Lebanon Libya Lithuania Macedonia Malawi Malaysia Malta Mauritius Mexico Moldavia Montenegro The Netherlands New Zealand Nigeria Norway Oman Pakistan Peru The Philippines Poland Portugal Quatar Romania Russia Saudi Arabia Seychelles Serbia Singapore Slovakia Slovenia Somalia South Africa South Korea Spain Sudan Sweden Switzerland Syria Taiwan Tajikistan Tanzania Thailand Turkey Turkmenistan USA Uganda Ukraine United Arab Emirates United Kingdom Uruguay Uzbekistan Venezuela Vietnam Yemen for US residents Latest Press Releases 30.09.2014 Boehringer Ingelheim invests €100 million: Expanded Respimat® production in Dortmund 27.09.2014 Head-to-head Phase III trial demonstrates superior progression-free survival for afatinib compared to erlotinib in patients with advanced squamous cell carcinoma of the lung - For Ex-US and Ex-UK Media Only 27.09.2014 Boehringer Ingelheim’s afatinib achieves primary endpoint in global Phase III study in recurrent/metastatic head and neck squamous cell cancer - For Ex-US and Ex-UK Media Only 26.09.2014 Nintedanib* receives positive CHMP opinion for second-line treatment of patients with adenocarcinoma of the lung - For media outside UK and US only 18.09.2014 Boehringer Ingelheim and CureVac announce collaboration to develop next generation lung cancer immunotherapy - For Ex-US and Ex-UK Media Only 16.09.2014 Type 2 Diabetes: Investigational empagliflozin/linagliptin combination tablet shows sustained reduction in blood glucose in Phase III study - For Non-U.S. and Non-UK Media Further press releases Biopharmaceuticals Manufacturing. Solutions. Partnering with us Working together Partnership with Ashoka Making More Health Activities back to top Connect with us Facebook - Company Page Pinterest - Online Pinboard Twitter - Global Channel YouTube - Our Video Channels Linkedin Mobile Website RSS Feed Job Search Accessibility Statement Terms of use Imprint RSS Feed Print Page Recommend © 2010 - 2014 Boehringer Ingelheim GmbH All rights reserved Accessibility statement Homepage Sitemap Search Contact Print